Finally, rates of obesity are constantly increasing among people with diabetes and contemporary recommendations for the management of the disease has put increased emphasis on use of certain GLP-1 receptors agonists for body weight control, such as liraglutide and semaglutide as well as the recently approved dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide which is highly effective in reducing body weight [6]. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.